IGFBP3 has been proven to exhibit an anti-tumor effect in a p53-dependent manner, and the down-regulation of IGFBP3 implicates with neuroendocrine differentiation, migration and invasion, and therapeutic sensitivity in various tumors [10–12]. This evidence concerns the gene IGFBP3 and neoplasm.